A comprehensive review of patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease

Abstract

The global prevalence of obesity and type 2 diabetes has increased, contributing to an increased worldwide prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD). Currently, one in three adults is affected by MASLD and/or its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), making this liver disease a significant public health challenge. Along with MASH-related cirrhosis, these conditions are poised to become the leading causes of chronic liver disease and liver transplants in the near future. Given the growing burden of MASLD and MASH, it is crucial to understand their impact from the patients’ perspective. One way to do this is by assessing patient-reported outcomes (PROs), including health-related quality of life (HRQL). HRQL can be assessed using generic instruments like the short form 36 version (SF-36) and the European quality of life-5 dimensions questionnaire (EQ-5D), or disease-specific tools such as the chronic liver disease questionnaire for nonalcoholic steatohepatitis (CLDQ-NASH). Given the limitations of each instrument, the best approach generally involves using both generic and disease-specific instruments. Evidence indicates that HRQL scores are significantly lower in individuals with MASLD, especially in areas assessing physical activity and the ability to perform daily living tasks. Fatigue and impaired work productivity are also important PROs for those with MASLD/MASH. These decrements in PROs worsen with disease progression but appear to improve with disease regression, including improvements linked to treatment. In this context, measuring PROs enhances the assessment of other patient-centric outcomes and provides insights for the healthcare community to develop interventions that could improve both clinical and humanistic outcomes for individuals living with MASLD/MASH.

Keywords

NAFLD / MAFLD / patient-reported outcome (PRO) / quality of life

References

[1] Younossi ZM,Paik JM,Van Dongen C.The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.Hepatology2023;77:1335-47 PMCID:PMC10026948

[2] Paik JM,Younossi Y,Alqahtani S.The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019.Hepatol Commun2023;7:e0251 PMCID:PMC10545420

[3] Younossi ZM,Younossi Y.Epidemiology of chronic liver diseases in the USA in the past three decades.Gut2020;69:564-8

[4] Younossi ZM,Abdelatif D,Henry L.Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016;64:73-84

[5] Sanyal AJ, Van Natta ML, Clark J, et al; NASH Clinical Research Network (CRN). Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med 2021;385:1559-69. PMCID:PMC8881985

[6] Simon TG,Khalili H,Ludvigsson JF.Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.Gut2021;70:1375-82 PMCID:PMC8185553

[7] Park H,Liu X.Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study.J Intern Med2019;286:711-22 PMCID:PMC6851415

[8] Younossi ZM,Stepanova M,Alqahtani S.Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.J Hepatol2024;80:694-701

[9] Golabi P,Eberly K,Alqahtani SA.Causes of death in patients with non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease and chronic viral hepatitis B and C.Ann Hepatol2022;27:100556

[10] Adams LA,Tilg H.Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.Gut2017;66:1138-53

[11] Ballestri S,Girolamo MD,Capitelli M.Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality.Metab Target Organ Damage2023;3:1

[12] Kalligeros M,Younossi ZM.Metabolic dysfunction-associated steatotic liver disease and its link to cancer.Metabolism2024;160:156004

[13] Mantovani A,Beatrice G.Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies.Gut2022;71:778-88

[14] Ekstedt M,Nasr P.Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.Hepatology2015;61:1547-54

[15] Younossi ZM,Ong J.Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States.Clin Gastroenterol Hepatol2021;19:580-9.e5

[16] Noureddin M,Bresee C.NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances.Am J Gastroenterol2018;113:1649-59 PMCID:PMC9083888

[17] Younossi ZM, Yilmaz Y, Yu ML, et al; Global NASH Council. Clinical and patient-reported outcomes from patients with nonalcoholic fatty liver disease across the world: data from the global non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD) registry. Clin Gastroenterol Hepatol 2022;20:2296-306.e6.

[18] Stepanova M,Younossi ZM.Economic burden and patient-reported outcomes of nonalcoholic fatty liver disease.Clin Liver Dis2023;27:483-513

[19] Younossi ZM,Henry L.The growing economic and clinical burden of nonalcoholic steatohepatitis (NASH) in the United States.J Clin Exp Hepatol2023;13:454-67 PMCID:PMC10213853

[20] US Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labelling claims. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. [Last accessed on 19 Nov 2024].

[21] Mercieca-Bebber R,Calvert MJ,Friedlander M.The importance of patient-reported outcomes in clinical trials and strategies for future optimization.Patient Relat Outcome Meas2018;9:353-67 PMCID:PMC6219423

[22] Cella DF.Measuring quality of life in palliative care.Semin Oncol1995;22:73-81

[23] Horsman J,Feeny D.The Health Utilities Index (HUI): concepts, measurement properties and applications.Health Qual Life Outcomes2003;1:54 PMCID:PMC293474

[24] van der Plas SM,de Boer JB.Generic and disease-specific health related quality of life of liver patients with various aetiologies: a survey.Qual Life Res2007;16:375-88

[25] Younossi ZM,Swain MG.Assessment of fatigue and its impact in chronic liver disease.J Hepatol2024;81:726-42

[26] Guyatt G,Norman G.Measuring change over time: assessing the usefulness of evaluative instruments.J Chronic Dis1987;40:171-8

[27] Cook CE.Clinimetrics corner: the minimal clinically important change score (MCID): a necessary pretense.J Man Manip Ther2008;16:E82-3 PMCID:PMC2716157

[28] US Food and Drug Administration. Incorporating clinical outcome assessments into endpoints for regulatory decision-making. Available from: https://www.fda.gov/media/132505/download. [Last accessed on 19 Nov 2024].

[29] Jaeschke R,Guyatt GH.Measurement of health status. Ascertaining the minimal clinically important difference.Control Clin Trials1989;10:407-15

[30] Ware JE Jr.The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.Med Care1992;30:473-83

[31] Devlin NJ.EQ-5D and the EuroQol group: past, present and future.Appl Health Econ Health Policy2017;15:127-37 PMCID:PMC5343080

[32] Coretti S,McNamee P.The minimum clinically important difference for EQ-5D index: a critical review.Expert Rev Pharmacoecon Outcomes Res2014;14:221-33

[33] EUROQQOL. EQ-5D-5L. Available from: https://euroqol.org/information-and-support/euroqol-instruments/eq-5d-5l/. [Last accessed on 20 Nov 2024].

[34] s Younossi ZM ,Kiwi M,King D.Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease.Gut1999;45:295-300 PMCID:PMC1727607

[35] Younossi ZM,Henry L.Performance and validation of chronic liver disease questionnaire-hepatitis C version (CLDQ-HCV) in clinical trials of patients with chronic hepatitis C.Value Health2016;19:544-51

[36] Younossi ZM,Younossi I.Development and validation of a hepatitis B-specific health-related quality-of-life instrument: CLDQ-HBV.J Viral Hepat2021;28:484-92

[37] Younossi ZM,Henry L.A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD.Liver Int2017;37:1209-18

[38] Younossi ZM,Younossi I.Development and validation of a primary sclerosing cholangitis-specific health-related quality of life instrument: CLDQ-PSC.Hepatol Commun2023;7:e0049 PMCID:PMC9894344

[39] Younossi ZM,Younossi I.Validation of a primary biliary cholangitis-specific version of chronic liver disease questionnaire: CLDQ-PBC.Clin Transl Gastroenterol2024;15:e1 PMCID:PMC11421712

[40] Younossi ZM,Younossi I.Validation of chronic liver disease questionnaire for nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic steatohepatitis.Clin Gastroenterol Hepatol2019;17:2093-100.e3

[41] Schulz KH,Ewers H,Younossi ZM.The factorial structure of the chronic liver disease questionnaire (CLDQ).Qual Life Res2008;17:575-84

[42] Gralnek IM,Kilbourne A.Development and evaluation of the liver disease quality of life instrument in persons with advanced, chronic liver disease-the LDQOL 1.0.Am J Gastroenterol2000;95:3552-65

[43] Kanwal F,Hays RD.Prospective validation of the short form liver disease quality of life instrument.Aliment Pharmacol Ther2008;28:1088-101

[44] FACIT.org. Functional assessment of chronic illness therapy - fatigue scale (FACIT-fatigue). Available from: https://www.facit.org/measures/facit-fatigue. [Last accessed on 19 Nov 2024].

[45] Kleinman L,Hakim Z.Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C.Qual Life Res2000;9:499-508

[46] Fisk JD,Ross L,Marrie TJ.Measuring the functional impact of fatigue: initial validation of the fatigue impact scale.Clin Infect Dis1994;18 Suppl 1:S79-83

[47] Reilly MC,Dukes EM.The validity and reproducibility of a work productivity and activity impairment instrument.Pharmaco economics1993;4:353-65

[48] Younossi ZM,Henry L.A comprehensive review of patient-reported outcomes in patients with chronic liver diseases.J Clin Gastroenterol2019;53:331-41

[49] Verma M,Younossi I,Abdelaal H.The impact of hepatocellular carcinoma diagnosis on patients’ health-related quality of life.Cancer Med2021;10:6273-81 PMCID:PMC8446553

[50] Younossi Z,Shrestha I.The burden of non-alcoholic steatohepatitis: a systematic review of health-related quality of life and patient-reported outcomes.JHEP Rep2022;4:100525 PMCID:PMC9418497

[51] Yamamura S,Hashida R.Patient-reported outcomes in patients with non-alcoholic fatty liver disease: a narrative review of chronic liver disease questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.J Gastroenterol Hepatol2021;36:629-36

[52] Barberá A,Arora AK,Lazarus JV.Patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease.Semin Liver Dis2024;Online ahead of print:

[53] Younossi ZM,Myers RP,Henry L.The potential role of fatigue in identifying patients with NASH and advanced fibrosis who experience disease progression.Clin Gastroenterol Hepatol2023;21:970-7.e1

[54] McSweeney L,Fattakhova G.Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis.JHEP Rep2020;2:100099 PMCID:PMC7229498

[55] Younossi ZM,Golabi P,Henry L.The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease: data from National health and nutrition examination survey 2005-2010 and 2017-2018.Liver Int2022;42:2646-61

[56] Weinstein AA,Kannan S.Interrelationship between physical activity and depression in nonalcoholic fatty liver disease.World J Hepatol2022;14:612-22 PMCID:PMC9055201

[57] Younossi ZM,Henry L.Lifestyle interventions in nonalcoholic fatty liver disease.Nat Rev Gastroenterol Hepatol2023;20:708-22

[58] Gerber LH,Mehta R.Importance of fatigue and its measurement in chronic liver disease.World J Gastroenterol2019;25:3669-83 PMCID:PMC6676553

[59] Austin P,Paik JM,Escheik C.Aerobic capacity and exercise performance in nonalcoholic fatty liver disease.J Sports Med Phys Fitness2019;59:1376-88

[60] Canada JM,Collen R.Relation of hepatic fibrosis in nonalcoholic fatty liver disease to left ventricular diastolic function and exercise tolerance.Am J Cardiol2019;123:466-73 PMCID:PMC6331258

[61] Mascaró CM,Montemayor S.Association between stages of hepatic steatosis and physical activity performance in adults with metabolic syndrome: a cross-sectional analysis in FLIPAN study.Nutrients2022;14:1790 PMCID:PMC9105320

[62] Weinstein AA,Oe B,Gerber LH.Perception of effort during activity in patients with chronic hepatitis C and nonalcoholic fatty liver disease.PM R2016;8:28-34

[63] Younossi ZM,Noureddin M.Improvements of fibrosis and disease activity are associated with improvement of patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis.Hepatol Commun2021;5:1201-11 PMCID:PMC8279457

[64] Younossi ZM,Taub RA,Harrison SA.Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life.Clin Gastroenterol Hepatol2022;20:1354-61.e7

[65] Schomerus G,Manthey J.The stigma of alcohol-related liver disease and its impact on healthcare.J Hepatol2022;77:516-24

[66] Wahlin S.Liver health literacy and social stigma of liver disease: a general population e-survey.Clin Res Hepatol Gastroenterol2021;45:101750

[67] Batchelder AW, Heo M, Foley JD, et al; HERO Study Group. Shame and stigma in association with the HCV cascade to cure among people who inject drugs. Drug Alcohol Depend 2023;253:111013.

[68] Smith-Palmer J,Sbarigia U.Impact of stigma on people living with chronic hepatitis B.Patient Relat Outcome Meas2020;11:95-107 PMCID:PMC7082540

[69] Younossi ZM, Alqahtani SA, Alswat K, et al; Global NASH Council. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease. J Hepatol 2024;80:419-30.

[70] Younossi ZM, AlQahtani SA, Funuyet-Salas J, et al; Global NASH Council. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease. JHEP Rep 2024;6:101066. PMCID:PMC11252535

[71] UNOS. Data and trends. Available from: https://unos.org/data/. [Last accessed on 19 Nov 2024].

[72] Serrano MT,Esteban LM.Mortality and causes of death after liver transplantation: analysis of sex differences in a large nationwide cohort.Transpl Int2022;35:10263 PMCID:PMC9124758

[73] Vitale A, Trapani S, Russo FP, et al; Associazione Italiana per lo Studio del Fegato (AISF).; Società Italiana Trapianti d’Organo (SITO).; Centro Nazionale Trapianti (CNT). Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: an Italian liver transplant registry study. JHEP Rep 2024;6:101147. PMCID:PMC11399673

[74] Stepanova M,Garg R,Saab S.Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis.BMC Gastroenterol2015;15:175 PMCID:PMC4678589

[75] Saab S,Ayoub N.Differences in health-related quality of life scores after orthotopic liver transplantation with respect to selected socioeconomic factors.Liver Transpl2011;17:580-90